Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

PRINCETON, N.J., Aug. 14 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, today announced its financial results for the second quarter of 2009.

DOR's revenues, which primarily relate to receipts from National Institutes of Health (NIH) grants, for the second quarter of 2009 were approximately $0.3 million compared to $0.5 million for the second quarter of 2008. Revenues for the first half of 2009 were approximately $0.9 million compared to $1.2 million for the first half of 2008. The decreased revenues were primarily attributable to lower support amounts drawn from DOR's Biodefense grants with the NIH.

DOR's net loss for the second quarter of 2009 was approximately $1.8 million, or $0.01 per share, compared to $1.3 million, or $0.01 per share, for the second quarter of 2008. The net loss for the first half of 2009 was approximately $3.9 million compared to $2.6 million for the first half of 2008. These larger net losses were primarily attributed to increased research and development (R&D) spending of $1.4 million for the first half of the year (or $391,000 for the second quarter) in preparation for the initiation of the confirmatory Phase 3 clinical trial of orBec((R)) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

R&D expenses for the second quarter of 2009 were approximately $1.1 million, compared to $0.7 million for the second quarter of 2008. R&D expenses for the first half of 2009 were approximately $2.7 million, compared to $1.3 million for the first half of 2008.

General and administrative (G&A) expenses for the second quarter of 2009 and 2008 were essentially flat year over year at $0.6 million, while G&A expenses for the first half of 2009 decreased to $1.1 million from $1.4 million for the first half of 2008. <
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... 5 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the Natixis,Bleichroeder Hidden Gems Conference ... presentation will begin at 2:45 p.m. Eastern Time in ... To access the live audio webcast or the subsequent ...
... Sigma-Aldrich Corporation,(Nasdaq: SIAL ), will hold ... on Wednesday, October 24, 2007, at 11:00 a.m. ... is being webcast by Thomson/CCBN and can be ... . The webcast is also being distributed ...
Cached Biology Technology:VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Sigma-Aldrich Corporation's 3rd Quarter 2007 Earnings Conference Call 2
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... face a suite of perilous threats in today,s ... and climate change, fragile coral ecosystems are disappearing ... trend, some species of corals surrounding the island ... protector in their tropical environment: coral guard-crabs. New ... Smithsonian Marine Station scientist Seabird McKeon and the ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... Assistant Professor of Pharmacology at LSU Health Sciences Center ... $1.2 million Research Project (RO1) grant by the National ... of Health. The 5-year grant will support his research ... brain in regulating blood pressure and the development of ...
... in Spanish . The journal " Science ... August the results of a detailed research work about the ... years. The study has been carried out with the participation ... Panama., The results obtained prove that the main concentrations of ...
... amounts of data are being generated in health care, ... these massive and unstructured data sets has proven cumbersome ... and visual analytics is helping sift through such mountains ... of a picture. The Georgia Institute of Technology ...
Cached Biology News:LSUHSC's Lazartigues awarded $1.2 million grant 2Fossil and molecular evidence reveals the history of major marine biodiversity hotspots 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
...
... revolutionary new application for DNA and ... interface, Expression makes complex computational analyses ... uses the very latest computing technology ... way sequences are analysed. Features include: ...
... Partek Genomics Solution is a ... interactive data visualization specifically designed to ... Designed for high-dimensional genomic studies containing ... is fast, memory efficient and will ...
Biology Products: